Back
Regeneron Pharmaceuticals, Inc. (REGN)
BiotechnologyREGN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$676.23
+4.07%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$41.48
ROE
14.5%
Gross margin
43.9%
Debt/Equity
8.61x
Revenue growth
19.0%
Regeneron Pharmaceuticals, Inc. — company intelligence
Earnings surprises
Q1 2026$9.47 vs $9.12 est+3.9%
Q4 2025$11.44 vs $10.83 est+5.7%
Q3 2025$11.83 vs $9.78 est+21.0%
Q2 2025$12.89 vs $8.61 est+49.8%
Insider activity · 90 days
0 buys10 sellsnet -278 shares
RYAN ARTHUR FSell 200 · Jul 2, 2026
RYAN ARTHUR FSell 2 · May 1, 2026
RYAN ARTHUR FSell 4 · May 1, 2026
Recent SEC filings
4 — Insider transaction reportJul 7, 2026
8-K — Material event reportJul 6, 2026
8-K — Material event reportJun 17, 2026
Latest news
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Regeneron Pharmaceuticals, Inc.
Weekly undervalued picks (like REGN)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.